Geoffrey R. Oxnard

Geoffrey R. Oxnard, MD, is the Chief Medical Officer at Foundation Medicine and a recognized authority on liquid biopsy and circulating tumor DNA (ctDNA) analysis in non-small cell lung cancer. Trained as a thoracic oncologist at Massachusetts General Hospital and Dana-Farber Cancer Institute, his clinical and research career has centered on developing and validating non-invasive genotyping approaches that can guide the selection and monitoring of targeted therapies. His work has been fundamental to establishing plasma genotyping as a clinically viable and increasingly preferred alternative to invasive tumor biopsy in patients with advanced NSCLC. Oxnard's research on plasma-based detection of the EGFR T790M resistance mutation was pivotal in supporting clinical programs for osimertinib, demonstrating that liquid biopsy could reliably identify patients who would benefit from third-generation EGFR inhibitor therapy. He validated the performance characteristics of commercially available cell-free DNA assays and contributed to regulatory deliberations about the role of plasma genotyping in drug approval processes. He also led work on ctDNA dynamics as pharmacodynamic and predictive biomarkers during targeted therapy, establishing frameworks now widely used in clinical trials. Since transitioning to his leadership role at Foundation Medicine, Oxnard has worked to scale genomic profiling for broader clinical adoption and to integrate ctDNA monitoring into routine oncology practice. He has been an active contributor to ASCO, IASLC, and guideline development panels, and remains a frequent author and speaker advancing the scientific and practical dimensions of liquid biopsy in thoracic oncology and beyond.